Introducing Signant Health
CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, launched as Signant Health - uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies, and Endpoint Quality into a patient-centric suite.
“The best technology in clinical research succeeds in the background,” said Mike Nolte, CEO of Signant Health. “We work to be expert, with proven solutions and scientific support that simplify research for patients, sponsors and CROs. I’m humbled to be a part of our customers’ important work, proud of the Signant Health team and excited to continue to innovate along every step of the patient journey.”
Signant Health combines a comprehensive, united suite of proven technologies with developers, project managers, data analysts, scientists and clinicians.
“The new Signant brand reflects our desire to help separate signal from noise at the intersection of science and technology and to never forget that our customers’ significant work matters locally and globally,” added Nolte. ”In 2018, CRF Health and Bracket brought together industry-leading technology and analytics solutions, renowned executive and scientific leaders, and 20 years of experience delivering exemplary service to life science companies worldwide. The birth of Signant Health marks the next phase in our journey and unlocks extraordinary opportunities to improve the patient’s journey as well.”
To learn more about Signant Health’s solutions, visit www.signanthealth.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
